Johnson & Johnson Aiming to Enroll One-Third of Phase 3 Trial Patients From Latin America

Johnson & Johnson (NYSE:JNJ) is looking south of the U.S. border for participants in a phase 3 clinical trial of its coronavirus vaccine candidate. The company said it aims to enroll 20,000 people from Latin America for the study, roughly one-third of the planned worldwide total.